Related Experiment Video

Updated: Aug 9, 2026

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

[Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer]

P D Zapata1, B Colas, P López-Ruiz

  • 1Departamento de Bioquímica, Universidad de Alcalá, Servicio de Urología, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid.

Actas Urologicas Espanolas
|July 14, 2004
PubMed

Insights

Somatostatin (SS) inhibits prostate cancer growth by activating the SHP-1 enzyme, which controls cell proliferation. This finding highlights SS as a potential therapeutic agent for prostate cancer management.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Context:

  • Prostatic growth is regulated by androgens and neuroendocrine secretions.
  • Prostate cancer progression involves complex cellular mechanisms.
  • Somatostatin (SS) is a neuroendocrine peptide with known inhibitory functions.

Purpose:

  • To review the mechanisms of prostatic growth.
  • To investigate the role of somatostatin (SS) in inhibiting neoplastic growth.
  • To elucidate the specific molecular pathways through which SS exerts its antiproliferative effects in the prostate.

Summary:

  • The antiproliferative effect of somatostatin (SS) on the prostate is mediated by the phosphotyrosine phosphatase SHP-1.
  • SHP-1 is present in human prostate tissue and plays a critical role in controlling prostatic cell proliferation.
  • This enzyme is implicated in the progression of prostate cancer, suggesting a direct link between SS, SHP-1, and cancer development.

Impact:

  • The findings confirm the antiproliferative role of SS in prostate cancer.
  • The identification of SHP-1 as a key mediator highlights its significance in prostate cancer biology.
  • The study suggests that the presence of SHP-1 may determine the therapeutic potential of SS for controlling prostate cancer.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...